Co-Authors
This is a "connection" page, showing publications co-authored by HENRY MARK KUERER and GAIANE MARGISHVILI RAUCH.
Connection Strength
3.344
-
Feasibility of breast conserving surgery alone in HER2-positive exceptional responders to neoadjuvant systemic therapy. Eur J Surg Oncol. 2024 Dec; 50(12):108613.
Score: 0.244
-
Eliminating Breast Surgery for Invasive Cancer with Exceptional Response to Neoadjuvant Systemic Therapy: Prospective Multicenter Clinical Trial Planned Initial Feasibility Endpoint. J Am Coll Surg. 2023 07 01; 237(1):101-108.
Score: 0.221
-
Eliminating breast surgery for invasive breast cancer in exceptional responders to neoadjuvant systemic therapy: a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2022 12; 23(12):1517-1524.
Score: 0.215
-
To Look or Not to Look? Yes to Nodal Ultrasound! J Breast Imaging. 2021 Nov 16; 3(6):659-665.
Score: 0.202
-
Identification of breast cancer patients with pathologic complete response in the breast after neoadjuvant systemic treatment by an intelligent vacuum-assisted biopsy. Eur J Cancer. 2021 01; 143:134-146.
Score: 0.189
-
Accuracy of Post-Neoadjuvant Chemotherapy Image-Guided Breast Biopsy to Predict Residual Cancer. JAMA Surg. 2020 12 01; 155(12):e204103.
Score: 0.189
-
Eliminating the breast cancer surgery paradigm after neoadjuvant systemic therapy: current evidence and future challenges. Ann Oncol. 2020 01; 31(1):61-71.
Score: 0.177
-
Patient Selection for Clinical Trials Eliminating Surgery for HER2-Positive Breast Cancer Treated with Neoadjuvant Systemic Therapy. Ann Surg Oncol. 2019 Oct; 26(10):3071-3079.
Score: 0.172
-
Ductal Carcinoma In Situ and Margins <2?mm: Contemporary Outcomes With Breast Conservation. Ann Surg. 2019 01; 269(1):150-157.
Score: 0.165
-
Optimal Selection of Breast Cancer Patients for Elimination of Surgery Following Neoadjuvant Systemic Therapy. Ann Surg. 2018 12; 268(6):e61-e62.
Score: 0.164
-
A Clinical Feasibility Trial for Identification of Exceptional Responders in Whom Breast Cancer Surgery Can Be Eliminated Following Neoadjuvant Systemic Therapy. Ann Surg. 2018 05; 267(5):946-951.
Score: 0.158
-
Biopsy Feasibility Trial for Breast Cancer Pathologic Complete Response Detection after Neoadjuvant Chemotherapy: Imaging Assessment and Correlation Endpoints. Ann Surg Oncol. 2018 Jul; 25(7):1953-1960.
Score: 0.157
-
Baseline factors predicting a response to neoadjuvant chemotherapy with implications for non-surgical management of triple-negative breast cancer. Br J Surg. 2018 04; 105(5):535-543.
Score: 0.156
-
DCIS Margins and Breast Conservation: MD Anderson Cancer Center Multidisciplinary Practice Guidelines and Outcomes. J Cancer. 2017; 8(14):2653-2662.
Score: 0.150
-
Identification of Patients With Documented Pathologic Complete Response in the Breast After Neoadjuvant Chemotherapy for Omission of Axillary Surgery. JAMA Surg. 2017 07 01; 152(7):665-670.
Score: 0.149
-
Multimodality Imaging for Evaluating Response to Neoadjuvant Chemotherapy in Breast Cancer. AJR Am J Roentgenol. 2017 Feb; 208(2):290-299.
Score: 0.142
-
Microcalcifications in 1657 Patients with Pure Ductal Carcinoma in Situ of the Breast: Correlation with Clinical, Histopathologic, Biologic Features, and Local Recurrence. Ann Surg Oncol. 2016 Feb; 23(2):482-9.
Score: 0.132
-
Clinicopathologic, mammographic, and sonographic features in 1,187 patients with pure ductal carcinoma in situ of the breast by estrogen receptor status. Breast Cancer Res Treat. 2013 Jun; 139(3):639-47.
Score: 0.113
-
Monitoring response to neoadjuvant chemotherapy in triple negative breast cancer using circulating tumor DNA. BMC Cancer. 2024 Aug 16; 24(1):1016.
Score: 0.061
-
Patient Interest in Exploring Nonsurgical Treatment Approaches for Early-Stage Breast Cancer: A Qualitative Study. Int J Radiat Oncol Biol Phys. 2024 Feb 01; 118(2):443-454.
Score: 0.057
-
Patient-Reported Outcomes of Omission of Breast Surgery Following Neoadjuvant Systemic Therapy: A Nonrandomized Clinical Trial. JAMA Netw Open. 2023 09 05; 6(9):e2333933.
Score: 0.057
-
Digital Breast Tomosynthesis for Intraoperative Margin Assessment during Breast-Conserving Surgery. Ann Surg Oncol. 2019 Jun; 26(6):1720-1728.
Score: 0.042
-
Correlation between sonographic findings and clinicopathologic and biologic features of pure ductal carcinoma in situ in 691 patients. AJR Am J Roentgenol. 2015 Apr; 204(4):878-88.
Score: 0.032